滤泡性甲状腺癌成功消融的临床意义
本研究纳入428例滤泡性甲状腺癌(FTC)患者(消融组216例,观察组212例),评估术后消融患者的临床特征、成功消融的预测因素及其与临床结局的关系。消融时甲状腺球蛋白水平是成功消融的唯一独立预测因素(OR 0.952;95%CI 0.909-0.996;P=.034)。成功消融患者10年病因特异性生存率和无远处转移生存率均达100%。
要点
- 消融组患者较观察组年龄更大、广泛浸润型FTC比例更高、血管侵犯≥2比例更高、抗甲状腺球蛋白抗体阳性率更高(P=.007)。
- 116例接受诊断性I-131闪烁扫描后术后消融的患者中,65例(56%)达到成功消融。
- 成功消融者10年无远处转移生存率为100%,未成功消融者为81.7%(P<.001)。
核心结论
- 成功消融的FTC患者10年病因特异性生存率和无远处转移生存率均达100%,即使存在不良预后因素,仔细随访可能也是不必要的。
研究设计与样本
- 研究纳入428例FTC患者(消融组216例,观察组212例),采用多因素logistic回归模型分析成功消融的独立预测因素。
主要发现
- 消融组患者较观察组年龄更大(P<.001),广泛浸润型FTC组织学比例更高(P<.001),血管侵犯≥2比例更高,抗甲状腺球蛋白抗体阳性率更高(P=.007)。
- 116例接受诊断性I-131闪烁扫描后术后消融的患者中,65例(56%)达到成功消融。
- 多因素分析显示,消融时甲状腺球蛋白水平是成功消融的唯一独立预测因素(OR 0.952;95%CI 0.909-0.996;P=.034)。
- 消融组中,成功消融者(n=65)与未成功消融者(n=151)的10年病因特异性生存率分别为100%和98.4%(P=.246)。
- 成功消融者与未成功消融者的10年无远处转移生存率分别为100%和81.7%(P<.001)。
关键数值与推荐
- 成功消融的独立预测因素:消融时甲状腺球蛋白水平(OR 0.952;95%CI 0.909-0.996;P=.034)。
- 成功消融者10年病因特异性生存率100%,未成功消融者98.4%(P=.246)。
- 成功消融者10年无远处转移生存率100%,未成功消融者81.7%(P<.001)。
临床怎么用
- 作者认为,成功消融的FTC患者10年病因特异性生存率和无远处转移生存率均达100%,即使存在不良预后因素,仔细随访可能也是不必要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Outcomes of postoperative ablation focused on follicular thyroid carcinoma (FTC) have not been fully investigated. OBJECTIVE: The purpose of this study is to investigate the clinical characteristics of patients with FTC who received postoperative ablation, the predictive factors for successful ablation, and the association between successful ablation and the clinical outcomes of FTC. PATIENTS: The study included 428 patients with FTC (216 in ablation group and 212 in observation group). A multivariate logistic regression model was used to identify factors independently associated with successful ablation. RESULTS: Patients in the ablation group were significantly older (P < .001), had a higher prevalence of widely invasive-FTC histology (P < .001), had vascular invasion ≥2, and had a higher rate of antithyroglobulin antibody positivity (P = .007) than patients in the observation group. Among the 116 patients with postoperative ablation following diagnostic I-131 scintigraphy, 65 (56%) achieved successful ablation. In the multivariate analysis, the thyroglobulin level at ablation was the only independent predictor of successful ablation (odds ratio 0.952; 95% CI 0.909-0.996; P = .034). Among the ablation group, the 10-year cause-specific survival (CSS) rates of patients with (n = 65) and without successful ablation (n = 151) were 100% and 98.4% (P = .246), respectively. None of the patients with successful ablation died during the follow-up period. The 10-year distant-metastasis-free survival (DMFS) rates of patients with and without successful ablation were 100% and 81.7% (P < .001), respectively. None of the patients with successful ablation experienced distant metastatic recurrence during the follow-up period. CONCLUSION: Patients with FTC with successful ablation achieved excellent 10-year CSS and DMFS rates of 100%. Therefore, careful follow-up may be unnecessary for these patients even if they have negative prognostic factors.
引用
- Yamazaki H, Sugino K, Katoh R, et al. Clinical Significance of Successful Ablation in Follicular Thyroid Carcinoma. J Clin Endocrinol Metab. 2025. PMID: 40464652. doi:10.1210/clinem/dgaf326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。